Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

被引：4

作者：

Manson, Guillaume ^{[1
]}

Brice, Pauline ^{[2
]}

Herbaux, Charles ^{[3
]}

Silva, Maria ^{[4
]}

Bouabdallah, Krimo ^{[5
]}

Deau-Fisher, Benedicte ^{[6
]}

Bouteloup, Juliette ^{[7
]}

de Collela, Jean Marc Schiano ^{[8
]}

Nicolas-Virelizier, Emmanuelle ^{[9
]}

Maerevoet, Marie ^{[10
]}

Ghesquieres, Herve ^{[11
]}

Bastard, Aspasia Stamatoulas ^{[12
]}

Antier, Chloe ^{[13
]}

Poizeau, Florence ^{[14
]}

Dercle, Laurent ^{[15
]}

Houot, Roch ^{[16
]}

机构：

[1] Univ Hosp Rennes, Dept Hematol, Rennes, France

[2] Hop St Louis, Dept Hematol, Paris, France

[3] CHRU Lille, Lille, France

[4] Inst Portugues Oncol Lisboa, Dept Hematol, Lisbon, Portugal

[5] Univ Hosp Bordeaux, Dept Hematol, Pessac, France

[6] Cochin Hosp, Dept Hematol, Paris, France

[7] Chalon Ctr Hosp, Dept Hematol, Chalon Sur Saone, Saone & Loire, France

[8] Inst Paoli Calmettes, Marseille, France

[9] Leon Berard Ctr, Dept Hematol, Lyon, France

[10] Hosp Jules Bordet, Brussels, Belgium

[11] Hosp Civils Lyon, Dept Hematol, Ctr Hosp Lyon Sud, Pierre Benite, France

[12] Henri Becquerel Ctr, Rouen, France

[13] Nantes Univ Hosp, Dept Hematol, Nantes, France

[14] Rennes Univ Hosp, Dept Dermatol, Rennes, France

[15] Inst Gustave Roussy, Dept Med Imaging, Villejuif, France

[16] CHU Rennes, Dept Hematol, Rennes, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122171

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1549

引用

页数：3

共 50 条

[1] Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
Manson, Guillaume
Brice, Pauline
Herbaux, Charles
Bouabdallah, Kamal
Antier, Chloe
Poizeau, Florence
Dercle, Laurent
Houot, Roch
HAEMATOLOGICA, 2020, 105 (11) : 2664 - 2666
[2] Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
Manson, G.
Brice, P.
Herbaux, C.
Silva, M. G.
Bouabdallah, K.
Deau, B.
Bouteloup, J.
Schiano, J. M.
Nicolas-Virelizier, E.
Maerevoet, M.
Ghesquieres, H.
Stamatoullas, A.
Antier, C.
Carlo-Stella, C.
de Charette, M.
Poizeau, F.
Dercle, L.
Houot, Roch
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (04) : 1144 - 1153
[3] Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G. Manson
P. Brice
C. Herbaux
M. G. Silva
K. Bouabdallah
B. Deau
J. Bouteloup
J. M. Schiano
E. Nicolas-Virelizier
M. Maerevoet
H. Ghesquieres
A. Stamatoullas
C. Antier
C. Carlo-Stella
M. de Charette
F. Poizeau
L. Dercle
Roch Houot
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1144 - 1153
[4] Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G. Manson
P. Brice
C. Herbaux
M. G. Silva
K. Bouabdallah
B. Deau
J. Bouteloup
J. M. Schiano
E. Nicolas-Virelizier
M. Maerevoet
H. Ghesquieres
A. Stamatoullas
C. Antier
C. Carlo-Stella
M. de Charette
F. Poizeau
L. Dercle
Roch Houot
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1699 - 1700
[5] Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma (vol 48, pg 1144, 2021)
Manson, G.
Brice, P.
Herbaux, C.
Silva, M. G.
Bouabdallah, K.
Deau, B.
Bouteloup, J.
Schiano, J. M.
Nicolas-Virelizier, E.
Maerevoet, M.
Ghesquieres, H.
Stamatoullas, A.
Antier, C.
Carlo-Stella, C.
de Charette, M.
Poizeau, F.
Dercle, L.
Houot, Roch
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (05) : 1699 - 1700
[6] Auranofin and the efficacy of anti-PD1 immunotherapy
Zhang, Yan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Sasse, Stephanie
Reddemann, Katharina
Diepstra, Arjan
Borchmann, Sven
Oschlies, Ilske
Schnitter, Antje
Engert, Andreas
Borchmann, Peter
Klapper, Wolfram
HAEMATOLOGICA, 2019, 104 (01) : E45 - E46
[8] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
Simeone, Ester
Grimaldi, Antonio M.
Ascierto, Paolo A.
MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
[9] Auranofin enhances the efficacy of anti-PD1 immunotherapy
Zhao, Zichen
Hu, Shichuan
Zhang, Yan
CANCER RESEARCH, 2024, 84 (06)
[10] Predicting the anti-PD1 response
Minton, Kirsty
NATURE REVIEWS IMMUNOLOGY, 2019, 19 (07) : 414 - 415

← 1 2 3 4 5 →